METTL3/14 and IL‐17 signaling contribute to CEBPA‐DT enhanced oral cancer cisplatin resistance-Reference-Cited by-同舟云学术

METTL3/14 and IL‐17 signaling contribute to CEBPA‐DT enhanced oral cancer cisplatin resistance

Published:2021-12-02 Issue: Volume: Page:
ISSN:1354-523X
Container-title:Oral Diseases
language:en
Short-container-title:Oral Dis

Author:

Qiao Xue¹²,Zhu Li¹,Song Rongbo¹,Shang Chao³,Guo Yan¹²

Affiliation:

1. Department of Central Laboratory School and Hospital of Stomatology Liaoning Provincial Key Laboratory of Oral Disease China Medical University Shenyang China

2. Department of Oral Biology School and Hospital of Stomatology Liaoning Provincial Key Laboratory of Oral Disease China Medical University Shenyang China

3. Department of Neurobiology China Medical University Shenyang China

Publisher

Wiley

Subject

General Dentistry,Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/odi.14083

Reference53 articles.

1. MEME SUITE: tools for motif discovery and searching

2. Clinical epigenetics: seizing opportunities for translation

3. MODOMICS: a database of RNA modification pathways. 2017 update

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

5. Recent advances in dynamic m 6 A RNA modification

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The two-faced role of RNA methyltransferase METTL3 on cellular response to cisplatin in head and neck squamous cell carcinoma in vitro model;Frontiers in Oncology;2024-06-19

2. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC;Oral Diseases;2024-02-20

3. RNA m6A modifications regulate crosstalk between tumor metabolism and immunity;WIREs RNA;2023-12-19

4. The IL-17 family in diseases: from bench to bedside;Signal Transduction and Targeted Therapy;2023-10-11

5. A novel oncogene trigger transposable element derived‐1 promotes oral squamous cell carcinoma progression via evoking immune inhibition;Molecular Carcinogenesis;2023-05-05